Maligní hypertermie "up‑to‑date prakticky" - nesystematický přehledový článek
| Title in English | Malignant hyperthermia ,,up -to -date practically" - non -systematic review article |
|---|---|
| Authors | |
| Year of publication | 2025 |
| Type | Article in Periodical |
| Magazine / Source | Anesteziologie a intenzivní medicína |
| MU Faculty or unit | |
| Citation | |
| web | https://aimjournal.cz/artkey/aim-202502-0002_malignant-hyperthermia-up-8209-to-8209-date-practically-non-8209-systematic-review-article.php |
| Doi | https://doi.org/10.36290/aim.2025.014 |
| Keywords | malignant hyperthermia; in vitro contraction test; next-generation sequencing; ryanodine receptor 1; dantrolene |
| Attached files | |
| Description | Malignant hyperthermia (MH) is a rare, hereditary, life-threatening pharmacogenetic disease induced by some commonly used anaesthetics. This review article aims to summarise, from a practical point of view, the news and current recommen- dations in the field of MH so that the anaesthesiologist-intensivist can easily use them in daily practice. The theoretical introduction is only brief, as it serves to gain an essential awareness of the issue of MH. As a matter of priority, we will look at the most common situations where a doctor may encounter MH. We will focus on the anaesthesiology clinic and the recognition of risk factors. In the operating room, preparation of the anaesthesia workplace for MH-risk patients and the management of the acute MH crisis are crucial. As part of intensive care, we will discuss the continuation of MH crisis therapy, and we will also mention situations when, in the case of unexplained rhabdomyolysis, it is worth considering MH. We will refer to the latest recommendations of the European Malignant Hyperthermia Group (EMHG) and briefly comment on their implementation in our conditions, e.g., recommendations regarding dantrolene availability. We will also not forget the approach to pregnant women at risk of MH. In conclusion, we will outline an outlook that reflects the current developments and future changes in the perspective on the issue of MH and explain why the centralisation of care for patients at risk of MH is so necessary. |
| Related projects: |